dPCR and qPCR Market Top Players and Business Intelligence
According to the new market research report dPCR and qPCR market is projected to reach USD 7.6 billion by 2025 from USD 4.9 billion in 2020, at a CAGR of 9.0% between 2020 and 2025.
Factors
such as the rising incidence of target infectious diseases and genetic
disorders; technological advancements in PCR technologies; increasing
investments, funds, and grants; increasing use of biomarker profiling
for disease diagnostics; and successful completion of the Human Genome
Project are driving the growth of this market. However, the high
instrument costs—especially that of dPCR—and the technical limitations
of PCR have restricted their greater use.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=174151204
The
global dPCR and qPCR market is highly competitive, with many large,
medium-sized, and small market players. As of the financial year ended
in March 2019, the global dPCR and qPCR market was dominated by Thermo
Fisher Scientific (US), Bio-Rad Laboratories Inc. (US), and F.
Hoffmann-La Roche, Ltd. (Switzerland).
Thermo Fisher Scientific
held the leading position in the dPCR and qPCR market in 2019. Thermo
Fisher Scientific focuses on strengthening its position in the market by
adopting organic and inorganic strategies such as product launches and
expansions. In line with this strategy, Thermo Fisher Scientific
launched several products, including the SureTect Cronobacter Species
Real-Time PCR Assay (2016), Axiom Africa Array (2017), QuantStudio 5
Real-Time PCR System (2017), and TaqMan Digital PCR Liquid Biopsy Assays
(2017). To combat the COVID-19 outbreak, Thermo Fisher Scientific also
developed several PCR kits and assays for diagnostics and research. It
received US FDA EUA for the SARS‑CoV‑2 multiplex real-time PCR test and
launched the AcroMetrix Coronavirus 2019 (COVID-19) RNA Control in 2020.
Bio-Rad
Laboratories is the second-largest player in the dPCR and qPCR market.
To further increase its share in the dPCR and qPCR market, the company
focuses on growth strategies such as acquisitions and new product
launches and approvals. During 2017–2019, Bio-Rad Laboratories witnessed
a steady rise in the profit margins and annual revenue of its Life
Science segment, mainly driven by the recent commercialization of its
dPCR and qPCR instruments, assays, and software. The company is focused
on the development and commercialization of innovative dPCR and qPCR
products that are highly efficient and can be used for clinical
diagnosis. In the last three years, Bio-Rad has also launched several
dPCR and qPCR products to meet the growing market demand for novel
clinical diagnostics. In addition to this, the acquisition of RainDance
Technologies in 2017 enabled Bio-Rad to strengthen its position in the
dPCR market.
Based on products & services, the qPCR market is
categorized into reagents and consumables, instruments and software
& services. The qPCR reagents and consumables segment is expected to
command the largest share of the qPCR products & services market in
2020.
Based on application, the market is categorized into
clinical applications (Infectious Disease Testing, Oncology Testing,
Blood Screening, Transplant Diagnostics and Other Clinical
Applications), research applications and forensic applications. The
clinical applications segment is estimated to dominate the qPCR
applications market in 2020.
Based on end users, the qPCR market
is segmented into research laboratories and academic institutes,
pharmaceutical and biotechnology companies, hospitals and diagnostic
centers, clinical research organizations (CROs), and forensic
laboratories. In 2019, the hospitals and diagnostic centers segment
accounted for the largest share of the market.
Request For Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=174151204
North
America accounted for the largest share of the dPCR and qPCR market,
followed by Europe in 2019. The large share of the North American
regional segment can be attributed to the increased adoption of
innovative and novel genomic analysis products (including advanced qPCR
and dPCR products), availability of R&D funding for genomic research
(coupled with the robust research infrastructure in the region),
expanding use of PCR techniques in clinical diagnostics & forensics,
and early commercialization of qPCR/dPCR products compared to other
regions.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Comments
Post a Comment